title: Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor.
abstract: The sphingosine-1-phosphate type 1 (S1P(1)) receptor is a new target in the treatment of auto-immune diseases as evidenced by the recent approval of FTY720 (Fingolimod). The ligand-binding pocket of the S1P(1) receptor has been generally characterised but detailed insight into ligand-specific differences is still lacking. The aim of the current study is to determine differences in ligand-induced S1P(1) receptor activation using an in silico guided site-directed mutagenesis strategy. S1P(1) mutant receptors (modifications of residues Y98(2.57), R120(3.28), F125(3.33)) were probed with a chemically diverse set of S1P(1) agonists (S1P, dihydro-S1P (dhS1P), R-, S- and racemic FTY720-P, VPC24191, SEW2871). Mutation of the R(3.28) residue generally results in a reduction of the potency of all ligands although the synthetic ligands including FTY720-P are less sensitive to these mutations. The Y(2.57)F mutation does not affect the potency of any of the ligands tested, but for all ligands except FTY720-P a significant decrease in potency is observed at the Y(2.57)A mutant. The F(3.33)A mutation significantly decreased the potency of FTY720-P and is detrimental for SEW2871 and VPC24191. The non-aromatic endogenous ligands S1P and dhS1P are less affected by this mutation. Our in silico guided mutagenesis studies identified new molecular determinants of ligand-induced S1P(1) receptor activation: 1) the flexibility of the polar head of the agonist to maintain a tight H-bond network with R(3.28) and 2) the ability of the agonist to make aromatic π-stacking interactions with F(3.33). Interestingly, FTY720-P has both chemical properties and is the only ligand that can efficiently activate the Y(2.57)A mutant.
authors.affiliation: Department of Pharmacology & Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: Pieter B
authors.initials: PB
authors.lastname: van Loenen
authors.forename: Chris
authors.initials: C
authors.lastname: de Graaf
authors.forename: Dennis
authors.initials: D
authors.lastname: Verzijl
authors.forename: Rob
authors.initials: R
authors.lastname: Leurs
authors.forename: Didier
authors.initials: D
authors.lastname: Rognan
authors.forename: Stephan L M
authors.initials: SL
authors.lastname: Peters
authors.forename: Astrid E
authors.initials: AE
authors.lastname: Alewijnse
mesh_terms: D000818:Animals; D019295:Computational Biology; D015195:Drug Design; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D011485:Protein Binding; D011487:Protein Conformation; D055550:Protein Stability; D049349:Receptors, Lysosphingolipid / Q000819:agonists* / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D000081025:Sphingosine-1-Phosphate Receptors; D013237:Stereoisomerism
chemical_list: D008024:Ligands; D049349:Receptors, Lysosphingolipid; C477362:S1PR1 protein, human; D000081025:Sphingosine-1-Phosphate Receptors